Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lorenzo Pilla

Showing results (11-20 of 37) with videos related to

Pageof 4
Sort By:
Oncoimmunology|April 9, 2016
Immunological markers and clinical outcome of advanced melanoma patients receiving ipilimumab plus fotemustine in the NIBIT-M1 studyCristina Maccalli, Diana Giannarelli, Filippo Capocefalo, et al.
Clinics and Research in Hepatology and Gastroenterology|June 22, 2022
MSI colorectal cancer, all you need to knowClémence Flecchia, Aziz Zaanan, Widad Lahlou, et al.
Cancer Research|September 20, 2006
Human tumor-released microvesicles promote the differentiation of myeloid cells with transforming growth factor-beta-mediated suppressive activity on T lymphocytesRoberta Valenti, Veronica Huber, Paola Filipazzi, et al.
Journal of Immunology (Baltimore, Md. : 1950)|April 22, 2004
Role of cross-talk between IFN-alpha-induced monocyte-derived dendritic cells and NK cells in priming CD8+ T cell responses against human tumor antigensDiego Tosi, Roberta Valenti, Agata Cova, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 20, 2007
Identification of a new subset of myeloid suppressor cells in peripheral blood of melanoma patients with modulation by a granulocyte-macrophage colony-stimulation factor-based antitumor vaccinePaola Filipazzi, Roberta Valenti, Veronica Huber, et al.
Cancer Research|April 3, 2003
Suboptimal activation of CD8(+) T cells by melanoma-derived altered peptide ligands: role of Melan-A/MART-1 optimized analoguesMatteo G Carrabba, Chiara Castelli, Markus J Maeurer, et al.
Oncoimmunology|May 6, 2015
A pilot Phase I study combining peptide-based vaccination and NGR-hTNF vessel targeting therapy in metastatic melanomaGiorgio Parmiani, Lorenzo Pilla, Angelo Corti, et al.
Breast (Edinburgh, Scotland)|September 7, 2018
Expression of NY-ESO-1, MAGE-A3, PRAME and WT1 in different subgroups of breast cancer: An indication to immunotherapy?Anna Tessari, Lorenzo Pilla, Damian Silvia, et al.
Expert Opinion on Biological Therapy|June 7, 2005
Escape strategies and reasons for failure in the interaction between tumour cells and the immune system: how can we tilt the balance towards immune-mediated cancer control?Licia Rivoltini, Paola Canese, Veronica Huber, et al.
Cancer Immunology, Immunotherapy : CII|December 31, 2011
Ex vivo enrichment of circulating anti-tumor T cells from both cutaneous and ocular melanoma patients: clinical implications for adoptive cell transfer therapyTonia Mazzarella, Valeria Cambiaghi, Nathalie Rizzo, et al.
Pageof 4

Showing results (11-20 of 37) with videos related to

Sort By:
Pageof 4
Oncoimmunology|April 9, 2016
Immunological markers and clinical outcome of advanced melanoma patients receiving ipilimumab plus fotemustine in the NIBIT-M1 studyCristina Maccalli, Diana Giannarelli, Filippo Capocefalo, et al.
Clinics and Research in Hepatology and Gastroenterology|June 22, 2022
MSI colorectal cancer, all you need to knowClémence Flecchia, Aziz Zaanan, Widad Lahlou, et al.
Cancer Research|September 20, 2006
Human tumor-released microvesicles promote the differentiation of myeloid cells with transforming growth factor-beta-mediated suppressive activity on T lymphocytesRoberta Valenti, Veronica Huber, Paola Filipazzi, et al.
Journal of Immunology (Baltimore, Md. : 1950)|April 22, 2004
Role of cross-talk between IFN-alpha-induced monocyte-derived dendritic cells and NK cells in priming CD8+ T cell responses against human tumor antigensDiego Tosi, Roberta Valenti, Agata Cova, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 20, 2007
Identification of a new subset of myeloid suppressor cells in peripheral blood of melanoma patients with modulation by a granulocyte-macrophage colony-stimulation factor-based antitumor vaccinePaola Filipazzi, Roberta Valenti, Veronica Huber, et al.
Cancer Research|April 3, 2003
Suboptimal activation of CD8(+) T cells by melanoma-derived altered peptide ligands: role of Melan-A/MART-1 optimized analoguesMatteo G Carrabba, Chiara Castelli, Markus J Maeurer, et al.
Oncoimmunology|May 6, 2015
A pilot Phase I study combining peptide-based vaccination and NGR-hTNF vessel targeting therapy in metastatic melanomaGiorgio Parmiani, Lorenzo Pilla, Angelo Corti, et al.
Breast (Edinburgh, Scotland)|September 7, 2018
Expression of NY-ESO-1, MAGE-A3, PRAME and WT1 in different subgroups of breast cancer: An indication to immunotherapy?Anna Tessari, Lorenzo Pilla, Damian Silvia, et al.
Expert Opinion on Biological Therapy|June 7, 2005
Escape strategies and reasons for failure in the interaction between tumour cells and the immune system: how can we tilt the balance towards immune-mediated cancer control?Licia Rivoltini, Paola Canese, Veronica Huber, et al.
Cancer Immunology, Immunotherapy : CII|December 31, 2011
Ex vivo enrichment of circulating anti-tumor T cells from both cutaneous and ocular melanoma patients: clinical implications for adoptive cell transfer therapyTonia Mazzarella, Valeria Cambiaghi, Nathalie Rizzo, et al.
Pageof 4